Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat […]
Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01
Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia […]
Peptilogics to Present Data in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection at ECCMID 2023
Peptilogics, a clinical-stage biotechnology company, has completed the enrollment of a Phase 1b trial for […]
Cantargia Treats First Triple-Negative Breast Cancer Patient in Randomized Phase II Part of TRIFOUR Trial
Cantargia today reported that, following positive results in the lead-in phase of the clinical phase […]
Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel […]
U.S.-based COBRA Diagnostic Prostate Cancer Trial Reaches Recruitment Target
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve […]
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]
Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors
Orano Med, a clinical stage radiopharmaceutical company, has announced that the first patient has been […]
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects
Armata Pharmaceuticals, a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial […]
Pfizer Progresses its Oral Receptor into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity
Sosei Group Corporation, the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more